Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

851
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
851
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

3.4K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Synthesis and Biological Evaluation of 4‑Bromo-<i>N,N-</i>dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.

ACS omega·2026
Same author

ASO Author Reflections: Atypical Breast Lesions on Core Needle Biopsy: Defining a Low-Risk Population to Guide Selective Surgical Excision.

Annals of surgical oncology·2026
Same author

Risk Stratification of Atypical Breast Lesions Diagnosed on Core Needle Biopsy: Toward Selective Surgical Excision.

Annals of surgical oncology·2026
Same author

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.

Journal of pharmaceutical and biomedical analysis·2026
Same author

α-Synuclein and γ-Tubulin Cooperatively Regulate Activity-Evoked Presynaptic Microtubule Nucleation to Gate Dopamine Release.

bioRxiv : the preprint server for biology·2026
Same author

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs.

ACS chemical neuroscience·2026

Video Experimental Relacionado

Updated: Jan 7, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K

Descifrando la farmacología de la matriz de la ibogaína: Modulación múltiple del transportador en las sinapsis de la

Christopher Hwu1, Václav Havel1, Xavier Westergaard2,3

  • 1Department of Chemistry, Columbia University, New York, New York 10027, United States.

Journal of the American Chemical Society
|December 26, 2025
PubMed
Resumen

La ibogaína y su metabolito noribogaína inhiben el transportador de monoaminas vesiculares 2 (VMAT2) y el transportador de serotonina (SERT). Esta doble acción, denominada "inhibidores de la recaptación sináptica" (SynRIs), explica la

Más Videos Relacionados

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K

Área de la Ciencia:

  • La neurociencia
  • Farmacología
  • La bioquímica

Sus antecedentes:

  • La ibogaína, derivada del árbol iboga, muestra potencial terapéutico para diversas afecciones neurológicas y psiquiátricas.
  • Comprender su mecanismo de acción implica examinar sus efectos en los transportadores de neurotransmisores monoamínicos.

Objetivo del estudio:

  • Investigar sistemáticamente los efectos de la ibogaína, la noribogaína y los análogos de la ibogaína en los transportadores de monoaminas.
  • Para aclarar los mecanismos neuroquímicos que subyacen a los efectos terapéuticos de la ibogaína.

Principales métodos:

  • Ensayos de fluorometría basados en células para evaluar la función de transporte de VMAT2.
  • Microscopía de dos fotones para visualizar la actividad del transportador en el cerebro del ratón.
  • Pruebas de absorción y liberación con serotonina radiomarcada en vesículas sinápticas cerebrales aisladas.
  • Pruebas de inhibición de los transportadores de monoaminas de membrana plasmática (MAT), incluidos los ensayos SERT y OCT2.

Principales resultados:

  • La ibogaína y la noribogaína inhiben el VMAT2 con una potencia submicromolar.
  • Se encontró que la noribogaína induce la liberación parcial de serotonina de las vesículas sinápticas.
  • Los compuestos de Iboga inhiben SERT y OCT2, con algunos análogos que muestran doble inhibición de VMAT2 y SERT.
  • Estos inhibidores duales fueron denominados "inhibidores de la recaptación sináptica" (SynRIs).

Conclusiones:

  • El perfil SynRI proporciona un modelo para los efectos neuroquímicos y el potencial terapéutico de la ibogaína.
  • Esta comprensión actualizada de la farmacología de iboga, denominada "farmacología de matriz", ayuda a explicar por qué la ibogaína no induce la catalepsia a diferencia de otros inhibidores de VMAT2.